Education
About Us
Working with TipRanks
Follow Us
Abbvie (ABBV)
:ABBV
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$163.81 - $218.66
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.06M
Market Cap
$366.65B
Enterprise Value$392.79B
Total Cash (Recent Filing)$5.18B
Total Debt (Recent Filing)$69.89B
Price to Earnings (P/E)100.2
Beta0.30
Next Earnings
Oct 24, 2025EPS Estimate
3.26Last Dividend Ex-Date
Jul 15, 2025Dividend Yield3.11%
Share Statistics
EPS (TTM)2.97
Shares Outstanding1,766,558,200
10 Day Avg. Volume4,842,564
30 Day Avg. Volume5,058,025
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue6.85
Enterprise Value/Gross Profit9.69
Enterprise Value/Ebitda26.50
Forecast
1Y Price Target
$221.19Price Target Upside6.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Acquisition And Pipeline ExpansionThe acquisition of Bretisilocin is a solid addition to AbbVie's Neuro pipeline and fits well with its fast-growing Neuro franchise, which is in the large Major Depressive Disorder category.
Earnings And Financial PerformanceAbbVie reported a big Q2 beat - with revenues at $15.4B, and EPS of $2.97, both exceeding consensus estimates.
Revenue GuidanceA second straight raise to revenue guidance, representing an $800mn increase to the prior guide.
Bears Say
Product PerformanceMore rapid deterioration of Humira counterbalances the upsides in R&S and Vyalev.
Sales DeclineSales in Aesthetics declined again sequentially due to economic challenges and low consumer sentiment.
AbbVie News
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $163.81 and its highest was $218.66 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $366.65B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Oct 24, 2025 which is in 57 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Jul 31, 2025. The company reported $2.97 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.09.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 3.11%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.26.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,558,200 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.97 in its last earnings report, beating expectations of $2.88. Following the earnings report the stock price went down -0.153%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$221.19 (6.57% Upside)
$221.19 (6.57% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 138.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.81%
12-Months-Change
Fundamentals
Return on Equity
112.90%
Trailing 12-Months
Asset Growth
-3.35%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies for complex diseases. Established in 2013 as a spinoff from Abbott Laboratories, AbbVie operates primarily in the sectors of immunology, oncology, neuroscience, and virology. Its core products include the blockbuster drug Humira, which treats autoimmune conditions, as well as other therapies like Imbruvica for cancer and Rinvoq for inflammatory diseases. The company is dedicated to addressing unmet medical needs through innovation and scientific advancement.
ABBV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant achievements in revenue growth, pipeline advancement, and strategic acquisitions. However, challenges remain in specific segments such as HUMIRA sales and the aesthetics market.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$221.19
▲(6.57% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
20.49% Mutual Funds
14.10% Other Institutional Investors
56.69% Public Companies and Individual Investors